Placenta Growth Factor in Eyes with Neovascular Glaucoma Is Decreased after Intravitreal Ranibizumab Injection.

Placenta Growth Factor in Eyes with Neovascular Glaucoma Is Decreased after Intravitreal Ranibizumab Injection.

PURPOSE:To evaluate changes in the concentrations of placental growth factor (PlGF) and vascular endothelial growth factor-A (VEGF-A) in aqueous humor of patients with neovascular glaucoma (NVG) before and after an intravitreal injection of ranibizumab (IVR) and to determine the underlying correlati...

Full description

Bibliographic Details
Main Authors:	Minwen Zhou, Jiawei Wang, Wei Wang, Wenbin Huang, Xiaoyan Ding, Xiulan Zhang
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2016-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4718677?pdf=render

Similar Items

Intravitreal Ranibizumab Injection as an Adjuvant in the Treatment of Neovascular Glaucoma Accompanied by Vitreous Hemorrhage after Diabetic Vitrectomy
by: Xi Shen, et al.
Published: (2016-01-01)

Intravitreal Bevacizumab (Avastin) Injection for Neovascular Glaucoma
by: Shahin Yazdani, et al.
Published: (2008-12-01)

Efficacy and safety of intravitreal ranibizumab with panretinal photocoagulation followed by trabeculectomy compared with Ahmed glaucoma valve implantation in neovascular glaucoma
by: Jin-Tao Sun, et al.
Published: (2017-03-01)

Neovascular events in eyes with central retinal vein occlusion undergoing serial bevacizumab or ranibizumab intravitreal injections: A retrospective review
by: Francis Char DeCroos, et al.
Published: (2014-01-01)

Multiple Intravitreal Ranibizumab Injections for Persistant Choroidal Neovascularization Associated with Presumed Ocular Histoplasmosis Syndrome
by: Turgut Yılmaz, et al.
Published: (2017-03-01)

Temporary Vitelliform Regression After Intravitreal Ranibizumab Injection for Macular Neovascularization Complicating Best Disease
by: Fayed A
Published: (2022-10-01)

Clinical Efficacy of Intravitreal Ranibizumab in Early and Mid-Idiopathic Choroidal Neovascularization
by: Chuanfeng Fan, et al.
Published: (2014-01-01)

Intravitreal Ranibizumab for Treatment of Posttraumatic Choroidal Neovascularization: a Case Report
by: A. N. Kulikov, et al.
Published: (2021-10-01)

Short-term results of intravitreal ranibizumab injection in eyes with diabetic macular edema
by: Ahmed Sharaf, et al.
Published: (2015-01-01)

Intravitreal cysticercosis presenting as neovascular glaucoma
by: Ratra Dhanashree, et al.
Published: (2010-01-01)

Assessment of effect of intravitreal ranibizumab injection on the ocular blood flow in patients with neovascular age-related macular degeneration
by: V. V. Neroev, et al.
Published: (2014-07-01)

The Use of Intravitreal Ranibizumab for Choroidal Neovascularization Associated with Vogt-Koyanagi-Harada Syndrome
by: A. M. Kolomeyer, et al.
Published: (2011-01-01)

Trabeculectomy with concurrent intravitreal bevacizumab in neovascular glaucoma
by: Sardar M Khan, et al.
Published: (2024-01-01)

Intravitreal ranibizumab injections in patients with retinopathy of prematurity (ROP)
by: Zuluaga Gómez, Liliana María, et al.
Published: (2018-01-01)

Rhizobium radiobacter Endophthalmitis following Intravitreal Ranibizumab Injection
by: Lavnish Joshi, et al.
Published: (2012-09-01)

Positive response to intravitreal ranibizumab in the treatment of choroidal neovascularization secondary to punctate inner choroidopathy.
by: Menezo, V, et al.
Published: (2010)

Intravitreal Ranibizumab Therapy for Choroidal Neovascularization Secondary to Pathological Myopia: 3 Year Outcome
by: İrfan Perente, et al.
Published: (2018-04-01)

Single intravitreal ranibizumab injection in eyes with acute non-arteritic anterior ischemic optic neuropathy
by: Preetam M Samant, et al.
Published: (2013-01-01)

Intravitreal triamcinolone acetonide as adjunctive treatment for neovascular glaucoma
by: Maria Teresa Brizzi Chizzotti Bonanomi, et al.
Published: (2005-08-01)

Severe Gemella haemolysans endophthalmitis following ranibizumab intravitreal injection
by: Silvia Olivia Salceanu, et al.
Published: (2017-01-01)

Treatment of Radiation Retinopathy with Intravitreal Injection of Ranibizumab (Lucentis®)
by: Horowitz SA, et al.
Published: (2020-02-01)

Chronic retinal detachment and neovascular glaucoma after intravitreal stem cell injection for Usher Syndrome
by: Kay T. Khine, et al.
Published: (2020-06-01)

Visual Performance in Patients with Neovascular Age-Related Macular Degeneration Undergoing Treatment with Intravitreal Ranibizumab
by: Sarah Sabour-Pickett, et al.
Published: (2013-01-01)

Genetic association with intravitreal ranibizumab response for neovascular age-related macular degeneration in Hispanic population
by: Francisco Jose Rodriguez, et al.
Published: (2019-01-01)

Comparison of visual acuity outcome and choroidal thickness variation of intravitreal ranibizumab injection for myopic choroidal neovascularization with or without dome-shaped macula
by: Xiao-Fang Yin, et al.
Published: (2024-12-01)

Recurrence of Macular Hole Retinal Detachment after Intravitreal Ranibizumab Injection for the Treatment of Choroidal Neovascularization from the Remaining Macular Hole Edge
by: Keiko Otsuka, et al.
Published: (2012-12-01)

Early Responses to Intravitreal Ranibizumab in Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
by: Wataru Matsumiya, et al.
Published: (2011-01-01)

Intravitreal Ranibizumab in the Treatment of Butterfly-Shaped Pattern Dystrophy Associated with Choroidal Neovascularization: A Case Report
by: Theodoros Empeslidis, et al.
Published: (2012-02-01)

Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration
by: Partha Biswas, et al.
Published: (2011-01-01)

Combination therapy of low-fluence photodynamic therapy and intravitreal ranibizumab for choroidal neovascular membrane in choroidal osteoma
by: Rodney J Morris, et al.
Published: (2011-01-01)

Comparison of Intravitreal Dexamethasone Implant and Ranibizumab in Vitrectomized Eyes with Diabetic Macular Edema
by: Jia-Kang Wang, et al.
Published: (2021-01-01)

An animal experimental study on the intravitreal injection of ranibizumab as an adjunctice treatment in retinoblastoma
by: Abd Aziz, Nor Azimah
Published: (2015)

Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys.
by: Alexander Tschulakow, et al.
Published: (2014-01-01)

Efficiency of Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration
by: Didem sahin, et al.
Published: (2015-12-01)

Comparison of risks of arterial thromboembolic events and glaucoma with ranibizumab and aflibercept intravitreous injection: A nationwide population‐based cohort study
by: Yin-Hsi Chang, et al.
Published: (2022-01-01)

Comparison of risks of arterial thromboembolic events and glaucoma with ranibizumab and aflibercept intravitreous injection: A nationwide population-based cohort study.
by: Yin-Hsi Chang, et al.
Published: (2022-01-01)

Inhibition of corneal neovascularization by subconjunctival injection of ranibizumab and bevacizumab in rabbit cornea
by: EKINCI M, et al.
Published: (2013-11-01)

Comparative Study of Oct Angiographic Finding in Diabetic Macular Edema After Intravitreal Triamicinilone Acetonide Injection and Intravitreal Ranibizumab Injection
by: Mohamad Abu El-Maaty, et al.
Published: (2022-10-01)

What is the impact of intravitreal injection of conbercept on neovascular glaucoma patients: a prospective, interventional case series study
by: Liukun Shi, et al.
Published: (2019-06-01)

Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab
by: Daniel Sanju Narayan, et al.
Published: (2015-01-01)